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ABSTRACT
Objective: To assess whether epidermal growth factor receptor (EGFR) and survivin 
immunostaining of tumour cells in urinary cytology and tissue of patients with bladder 
cancer has a prognostic significance.
Design: Prospective study
Setting: Department of Surgery (Division of Urology), Mubarak Al-Kabeer Teaching 
Hospital and Faculty of Medicine, Kuwait University, Kuwait
Subjects: Urine cytology smears obtained prior to cystoscopy in patients with transitional 
cell carcinoma (TCC) of the bladder were immunostained for EGFR and survivin. 
Bladder cancer tissue resected at surgery was also immunostained for EGFR and 
survivin expression. Tissue expression of EGFR and survivin in TCC of the bladder 
was compared to their expression in urine cytology and relationship to tumour grade 
and stage.
Results: 178 patients were studied (43 newly diagnosed bladder cancer, 58 with recurrent 
TCC and 77 in disease remission). Twenty five patients with normal urothelium served as 
controls. The mean sensitivity of urine cytology, tissue survivin immunohistochemistry 
(IHC) and tissue EGFR IHC was 30.5%, 62% and 59% respectively. The corresponding 
mean specificity was 95%, 79% and 38% respectively. For grades 1, 2 and 3 bladder 
tumors, tissue expression positivity for EGFR was 47.8%, 92.9%, 100% and for tissue 
survivin it was 27.8%, 18.2% and 33.3% respectively. For grades 1, 2 and 3 bladder 
tumors, urine expression positivity for EGFR was 35.7%, 40% and 67.7% and for urine 
survivin it was 8.3%, 42.9% and 33.3% respectively.
Conclusion: Positive EGFR immunostaining of urine cytology specimen or tumour tissue 
increases with histological grade of TCC of the bladder. Survivin expression is less 
consistent in both urine cytology specimen and tissue samples. EGFR immunostaining 
may provide a useful tool in the grading of bladder TCC and aid in the selection of  
patients that may benefit from administration of EGFR inhibitors.
INTRODUCTION
Currently, clinical stage (TNM category) is the 
most important prognostic factor influencing the 
outcome of treatment of transitional cell carcinoma 
(TCC) of the urinary bladder (1, 2). However, using 
the clinical stage to predict the outcome of patients 
with muscle-invasive bladder cancer treated with 
cystectomy is less accurate compared to pathological 
staging because of a tendency to under- or over-stage 
when clinical evaluation is used (3, 4). For muscle-
invasive bladder tumours, cystectomy remains the 
best treatment option as 18-35% of patients with 
muscle-invasive disease will die from progressive 
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disease (4). Consequently, other prognostic markers 
are needed to improve the outcome of treatment of 
patients with muscle-invasive TCC of the bladder (1).
 Advances in molecular biology in the past three 
decades have increased our understanding of the 
pathways that are altered in neoplastic cells. It has 
been suggested that protein expression profiling 
of TCC of the bladder offers an alternative means 
to distinguish aggressive tumour biology and may 
improve the accuracy of outcome prediction in 
patients treated with cystectomy (5). It has been 
shown that, structural and functional defects in 
key gate keepers of the cell cycle such as p53, p21, 
p27 cyclin E1 etc are common in human TCC of the 
bladder and have been associated with poor urologic 
outcomes (6-9). Many studies have reported that 
the accumulation of evidence on altered expression 
of many of these markers have added important 
prognostic information in patients with TCC of the 
bladder treated by radical cystectomy (5, 10, 11). 
Furthermore, the advent of immunohistochemical 
(IHC) techniques for the detection and quantitation 
of these markers has been shown to be useful in 
predicting tumour behaviour independent of classical 
prognostic factors (13). Two molecular markers are 
currently under assessment for use in addition to 
traditional staging techniques to assist in the staging 
of urothelial cancer. The 2 markers are epidermal 
growth factor receptor (EGFR) and survivin (14-22).
 EGFR protein expression in bladder cancer is 
associated with increasing pathological grade and 
stage and higher rates of recurrence and disease 
progression [14, 15, 16]. Clinical studies have also 
shown both by molecular methods and IHC that 
there is a correlation between the levels of mutated 
p53 protein and muscle-invasive bladder cancer (13, 
17, 18). Furthermore, EGFR is present in the urine of 
patients with bladder TCC.  
 Survivin is a member of the inhibitor of apoptosis 
protein family. It inhibits apoptosis via blocking 
caspase activation as do other inhibitors of apoptosis. 
It is also expressed in the G2/M phase of the cell cycle 
and has been shown to be involved in the regulation 
of chromosome alignment and segregation (19). 
Expression of survivin in this phase may allow cells 
to overcome an apoptotic checkpoint, thus favoring 
aberrant progression through mitosis (20). Survivin 
has been shown to be highly expressed in many types 
of cancer cells including urothelial carcinoma (21). 
Its non-detection in non-proliferating normal adult 
tissues, makes it an attractive cancer therapeutic target 
(20). Even though some inconsistent results were 
obtained on the prognostic value of survivin protein 
or its messenger RNA (mRNA) level among many 
early studies in urothelial carcinoma, several recent 
studies using IHC or real-time quantitative reverse 
transcription-polymerase chain reaction (RT-PCR) 
have suggested that survivin expression may be a 
promising prognostic marker that correlates with 
unfavorable disease-specific survival and recurrence 
(22-24). In addition,  survivin has also been proposed 
as a urine marker for early bladder cancer detection 
or detection of recurrence during follow-up (25, 26). 
This is because survivin is present in the urine of 
patients with urothelial cancer (25, 26).
 In the present study, we correlated EGFR and 
survivin expression in bladder cancer tissues with 
other histopathological parameters. In addition, we 
correlated level of expression of EGFR and survivin 
in urine sediments obtained for urine cytology with 
the final histological grade of the resected tumours. 
We further determined the ability of tissue EGFR and 
survivin expression to diagnose bladder cancer in 
patients with newly diagnosed, recurrent TCC and 
patients with known TCC of bladder but in remission 
during surveillance.
PATIENTS & METHODS 
Voided urine samples were obtained from patients 
with suspected TCC of the bladder (newly diagnosed 
patients), patients with known bladder TCC about 
to undergo scheduled surveillance check cystoscopy 
and patients with lower urinary symptoms requiring 
cystoscopy or elderly men with no LUTS requiring 
cystoscopy (normal urothelium). Urine specimens 
were sent for urine cytology and urine cytology 
smears (the slides) obtained were subsequently 
used for immunocytochemical assessment for  the 
presence or absence of EGFR and survivin expression. 
All urine cytology and urine cytology EGFR and 
survivin expression were assessed by one experienced 
cytopathologist (KK).
 All cystoscopic procedures and biopsies were 
carried out by an experienced urologist (EOK). 
Patients underwent transurethral resection of bladder 
tumour (TURBT) at diagnosis, or during surveillance 
cystoscopy if tumour was present. All tissues resected 
were subjected to routine histological procedures and 
sections stained with H&E for assessment of tumour 
grade and stage.  These were determined by one 
experienced histopathologist (JTA). Tissue samples 
were further processed for IHC expression of EGFR 
and survivin. All IHC were graded positive (+ve) or 
negative (–ve) by one pathologist JTA. 
 The sensitivity, specificity, positive predictive 
value (PPV), negative predictive value (NPV) and 
diagnostic accuracy of urine cytology, tissue EGFR 
and survivin expression on IHC in patients with 
newly diagnosed or recurrent TCC were determined 
and compared. Tumour grade was also compared 
with tissue EGFR and survivin expression. Similarly, 
tumour grade was also compared with EGFR and 
survivin expression in urine cytology smears. The 
final clinical stage of each tumour was determined 
in conjunction with findings at pre-operative IVU, 
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bone scan, CT scan and findings during cystoscopy 
including examination under anaesthesia (EUA). The 
final pathological grade was determined based on 
tissue resected at surgery using the WHO criteria of 
low grade (grades 1 and 2) and high grade (grade 3). 
We used clinical staging and not pathological stage 
because not all the patients had radical cystectomy.
 Patients with known UTI, recent history 
of intravesical chemotherapy were excluded 
from the study as were patients with a final 
histological diagnosis of squamous cell carcinoma 
or adenocarcinoma. Patients with TCC of the renal 
pelvis and ureter were also excluded from this study. 
The study received local Ethical Committee approval 
and patients signed relevant informed consent forms.
Preparation of urine samples for cytopathological 
examination: Urine samples received (ranged from 
5ml to 40ml) was concentrated by centrifugation 
(600g for 10 minutes). The supernatant was poured 
off and the cell pellet was vortexed to resuspend it. If 
the cell pellet was clear, 1 ml of PreservCyt solution 
was added, vigorously vortexed and four cytospins 
prepared on a ThermoShandon cytocentrifuge. If the 
cell pellet had a bloody appearance, 30 ml of CytoLyt 
solution was added to the cell pellet, centrifuged at 
600g for 10 minutes, supernatant poured off and 
cell pellet vortexed prior to adding PreservCyt 
solution. Papanicolaou staining was done on one of 
the cytospins. The remaining cytospins were fixed 
in 95% ethanol and stored at -20ºc till staining was 
carried out. Immunostaining for EGFR and survivin 
was carried out on two of the cytospins and the 
remaining was stored at -20ºC as a reserve.
Immunostaining procedure for urine survivin and EGFR 
expression and scoring system: The cytospins slides 
stored in the deep- freezer were again dipped in 95% 
alcohol for 30 minutes and then dehydrated. These 
were then quenched with 3% hydrogen peroxide 
to suppress endogenous peroxidase staining. After 
treatment with blocking reagent (Protein block, 
DAKO X0909) which prevents non-specific binding 
of subsequent reagents, samples were incubated with 
survivin (1:50) (Survivin D-8, sc 17779, Santacruz) 
and EGFR (1:50) overnight at 4ºC. Link antibody was 
added for 20 minutes followed by streptavidin-biotin 
(LSAB-DAKO) kit. Detection was achieved using a 
chromogen substrate solution diamino benzidine 
(DAB) [DAKO, S3000] and hydrogen peroxide. Slides 
were rinsed thrice with PBS after each step. The 
samples were counterstained with haematoxylin, 
dehydrated by passing through graded alcohols, 
cleared in xylene and mounted with DPX mountant. 
With each batch a positive control for survivin 
(normal stomach) and EGFR (placenta) was run. 
Pressure cooking in citrate buffer (0.01M, pH6.0), 
for eight minutes was done for the survivin control 
and enzymatic pepsin digestion for 10 minutes at 37 
oC was done for EGFR control for antigen retrieval. 
Negative controls were run by omitting the primary 
antibody. Figures 1 and 3 show some positive survivin 
and EGFR expression respectively on urine cytology 
smears.
Figure 1
Survivin expression on urine cytology specimen  
(x 400)
Figure 2
Survivin expression on resected  bladder TCC tissue  
(x 1000)
Figure 3a
EGFR expression on urine cytology specimen (x 200)
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Figure 3b
EGFR  expression on urine cytology  specimen ( x 400)
Survivin IHC: The technique used was similar 
to those described by Chen et al 2008 (19). 
Immunohistochemical staining for survivin (D-8, 
Santacruz Biotechnology, Santacruz, California, 
USA) was performed on formalin-fixed, paraffin-
embedded, 5-µm tissue sections following appropriate 
antigen retrieval on the BondMax Autostainer 
(Vision BioSystems Inc, Norwell, Mass) using the 
Bond Polymer Define Secondary Detection System 
and using diaminobenzidine as the chromogen 
(Vision BioSystems). The selected survivin antibody 
was a mouse monoclonal antibody raised against 
aminoacids 1 to 142 of human survivin. An example 
of a positive tissue survivin expression is shown on 
Figure 4.
Figure 4
Positive tissue survivin  expression in grade 3 TCC 
bladder. Survivin shows nuclear staining (x 250)
EGFR IHC: The technique used involved antigen 
retrieval by pepsin digestion and use of appropriate 
blocking solution. Primary antibody was followed 
by biotinylated link LSAB (Dako, Carpinteria, 
USA). DAB was used as chromogen, on IHC, EGFR 
positivity was as previously defined by Sriplakich 
et al 1999 (2). A tumour where ≥ 20% of the tumour 
cells, with the exception of those in the basal layer, 
showed membrane staining to the EGFR antibody 
in at least one of the examined fields (≥ 200) was 
defined as being EGFR-positive. In all other cases 
the tumour was considered EGFR-negative. When a 
tumour was EGFR-positive in only one or two fields, 
it was considered to be focally EGFR-positive. If 
stained areas were found in more than two fields, the 
tumour was considered to be diffusely EGFR-positive. 
An example of a positive tissue EGFR expression is 
shown on Figure 5.
Figure 5
Positive tissue EGFR  expression in grade 3 TCC 
bladder. EGFR shows membrane staining (x 250)
Urine samples not analysable: Some urine specimens 
were not analysable for the following reasons:
for urine cytology, there was little or no cellular 
materials after cytospin to enable the cytopathologist 
make a definite diagnosis about the absence or 
presence of malignant cells. This was true for patients 
with small bladder cancer or those with very tiny 
recurrences: or EGFR and survivin  immunostaining 
tests some results were equivocal, ie neither positive 
or negative or too few cellular material was present 
to make a definitive diagnosis. This was true for 
patients with very small bladder tumours or those 
with tiny recurrences.  
 We excluded these categories of urine samples 
from further analysis, based on the premise that we 
would consider a test +ve or –ve  if we had enough 
cellular material  to make a correct diagnosis. 
Definitions:
In this study, the following definitions have been used;
Sensitivity    = TP/TP + FN (i.e. tumour +ve),
Specificity  = TN/TN +FP (i.e. tumour –ve),
PPV   = TP/TP + FP
NPV  = TN/TN + FN     and
Diagnostic accuracy = TP+TN/n, where n = TP + 
FN + FP + TN.
Where T= true, N= negative, F= false, P= positive, 
PPV = positive predictive value and NPV = negative 
predictive value.
The sensitivity, specificity, PPV, NPV of urine cytology, 
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tumour tissue EGFR IHC staining, tumour tissue 
survivin IHC staining, urine sediment EGFR staining 
and urine sediment survivin staining were compared 
in patients with newly diagnosed TCC, patients 
with recurrent bladder TCC and the urothelium of 
those without tumour recurrence after cystoscopy 
and bladder biopsy. Factors affecting the sensitivity 
of the test (i.e. giving false +ve test results) were 
analysed. Furthermore, we analysed the effect of the 
final histological grade and stage of tumour on the 
sensitivity of each test.
STATISTICAL ANALYSIS 
 All data management and analysis were conducted 
using the SPSS software (SPSS Inc, Chicago, IL). The 
chi square (χ2) or Fischer’s exact test was used to 
examine the association between categorical variables, 
and the normal Z test was used to assess the significant 
difference between two proportions. The t test was 
used to compare the means of two independent 
groups. A p value of <0.05 was considered statistically 
significant.
RESULTS 
Table 1 shows the mean age (range), pathological 
stage and grade of the patients studied. The patients 
were fairly representative of each stage and grade of 
the disease. A total of 203 patients were studied (164 
males, 39 females). The mean age of the patients was 
52 ± 10.7 years. There were 43, 58 and 77 patients with 
newly diagnosed TCC, recurrent TCC and known 
TCC but in remission respectively, 25 patients who 
underwent cystoscopy but had no bladder outlet 
obstruction were used as controls. Bladder biopsies 
in the control group showed neither inflammation 
nor the presence of urothelial tumour. Patients with 
newly diagnosed bladder TCC had higher stage 
disease compared with those who had recurrent 
disease. Most of our patients presented with low 
grade disease as shown in Table 1. 
Table 1
Pathological grade, stage and profile of patients with bladder cancer
Grade Total 
number 
Newly Diagnosed** Recurrent** In remission Control +Gross Total
of 
cases*
No % No % p** No % No %
1 55 23 53.5 32 55.2 0.09 45 58.4 100 56.2
2 36 13 30.2 23 39.7 0.06 27 35.1 63 35.4
3 10 7 16.3 3 5.1 0.001 5 6.5 a 15 8.4
Total (n) 101 43 100 58 100  77 100 25 203 100
Stage Total Newly Diagnosed** Recurrent** In remission Control
No % No % p** No %
CIS 6 4 9.3 2 3.4 0.001 9 11.7 15 8.4
Superficial
pTa 6 4 9.3 2 3.4 0.001 22 28.6 28 15.7
pT1 54 17 39.5 37 63.9 0.1 42 54.5 96 53.9
Invasive
pT2 16 7 16.3 9 15.5 0.1 4 5.1 20 11.2
pT3 9 5 11.5 4 6.9 0.07 0 0 9 5.1
pT4 10 6 14.0 4 6.9 0.001 0 0 10 5.6














*The numbers shown in this column of the table represent total number of patients recruited and with tissue 
available for histological analysis following bladder biopsy or TURBT.
** Fischer’s exact test
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+Gross total includes patients with disease, those in remission and control subjects.
 ‘a’ patients with grade 3 or stage >PT1 urothelial tumour considered for cystectomy except it was very 
focal in nature or patient was subjected to partial cystectomy.
Table 2
Performance characteristics of urine cytology, survivin and EGFR immunohistochemistry on tissues obtained from 
patients with bladder cancer, but who had no tumour recurrence at follow up cystoscopy + bladder biopsy
Types of patients Remission (Tissue Diagnosis)*
Test Urine cytology (n=56) N (%) EGFR on IHC BT 
(n=21) N (%)
Survivin on IHC BT 
(n=28) N (%)
False positive 3 (5.4) 13 (62) 6 (21)
True negative 53 (95) 12 (38) 22 (79)
n: represented the number of tests performed for each marker out of 77 patients in remission. Patients 
whose  urine samples were not used for UC, EGFR or survivin IHC had very few cells in the urine – 
under the category of patients with TCC bladder in remission.
IHC BT = immunohistochemistry on bladder tissue
*Diagnosis based on histology of tissue biopsy.  
Table 3
Performance characteristics of urine cytology, survivin and EGFR immunohistochemistry on bladder tissue 
specimens in patients with bladder cancer.
Tests Test N D 
TCC
R C T 
TCC
Test N D 
TCC
R C T 
TCC
Test N D 
TCC
R C T 
TCC
1.Sensitivity UC 28.0% 33.0% S u r v i v i n 
IHC BT
63.0% 61.0% EGFR IHC 
BT 
57.0% 61.0%
2.Specificity UC 95.0% 95.0% S u r v i v i n 
IHC BT
79.0% 79.0% E G F R I H C 
BT
38.0% 38.0%
3. PPV UC 84.9% 86.8% S u r v i v i n 
IHC BT
75.0% 72.3% EGFR IHC 
BT
48.0% 49.6%
4. NPV UC 84.1% 58.6% S u r v i v i n 
IHC BT





UC 62.0% 64.0% S u r v i v i n 
IHC BT
71.0% 70.0% EGFR IHC 
BT
47.5% 48.5%
UC = urine cytology, 
ND TCC = newly diagnosed TCC
RCT TCC = recurrent TCC
IHC BT = immunohistochemistry on bladder tissue
Table 4
Comparison of EGFR and survivin expression on urine cytology specimen with corresponding histological grades of 
bladder tumour resected
Histological Grade UCS EGFR +ve UCS Survivin +ve p
1 (n = 5/14) 35.7% 1,6 (n = 1/12) 8.3% 1,7 1p = 0.001
2 (n = 2/5) 40% 2 (n = 3/7) 42.9% 2 2p = 0.15
3 (n = 4/6) 67.7% 3,6 (n = 2/6) 33.3% 3,7 3p = 0.2
No recurrence (n = 5/30) 16.7% 4 4p = 0.001
Normal Urothelium (Control) (n = 15/27) 18.5% 5 5p = 0.04
Fischer’s Exact test =  1-5p. 
‘Z’ test for trend =  6,7p. 6p = 0.01, 7p = 0.001
UCS = urine cytology specimen 
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Table 5
Comparison of tissue EGFR and survivin expression with corresponding histological grade of bladder tumour 
resected
Histological Grade Tissue EGFR +ve Tissue Survivin +ve p
1 (n = 11/23) 47.8% 1,4 (n = 5/18) 27.8% 1,5 1p  = 0.2
2 (n = 13/14) 92.9% 2 (n = 2/11) 18.2% 2 2p = 0.001
3 (n = 9/9) 100% 3,4 (n = 1/3) 33.3% 3,5 3p = 0.001
No recurrence (n = 13/28) 46.4% 6 (n = 6/28) 21.4% 6 6p = 0.06
Normal Urothelium (Control) (n = 8/25) 32% 7 (n = 6/25) 24% 7 7p = 0.3
Fischer’s Exact test (1,2,3,6,7p)
‘Z’ test for trend:  4p = 0.01, 5p = 0.2
The sensitivity of urine cytology, tissue survivin 
expression (+ve or –ve) and EGFR tissue expression 
(+ve or –ve) are shown in Tables 2 and 3. Similarly, 
the specificity, PPV, NPV of each test for all categories 
of patients and controls are shown in Tables 2 and 3.
 Table 4 and Figures 1 and 3 show the positivity 
of EGFR and survivin expression on urine cytology 
smears compared with the final tissue diagnosis 
and tumour grade. The EGFR expression increased 
from 35.7% to 67.7% for grade 1 to grade 3 tumours. 
There was inconsistent expression of survivin on 
urine cytology smears. EGFR expression both on 
tissue and urine cytology smears increased with the 
tumour grade. The normal urothelium also showed 
minor EGFR and survivin expression in about equal 
proportion for each marker as shown in Table 4. 
Table 5 and Figures 2, 4 and 5 show the relationship 
between  tumour grade on positivity of tissue EGFR 
and Survivin expression. There was progressive 
increase in expression of tissue EGFR from 47.8% 
in well differentiated cancers to 100% in poorly 
differentiated TCC. The tissue expression of survivin 
was inconsistent.
DISCUSSION
TCC of the bladder is currently the commonest 
urological neoplasm in the Middle East for two major 
reasons, the high prevalence of tobacco smoking and 
the high prevalence of Schistosoma haematobium 
infection in many parts of the Middle East. From 
tTable 1, our patients also presented at an earlier age 
compared to those reported in the literature and more 
than 80% were current or ex-smokers. Superficial 
bladder tumours are amenable to TURBT in addition 
to intravesical chemotherapy. However, for patients 
with invasive disease, treatment is by cystectomy. 
It has been reported that a significant proportion of 
patients treated by cystectomy will experience relapse 
of their disease owing to unrecognized and untreated 
nodal or distant metastases at the time of surgery. 
Hence, the need for a search for better prognostic 
markers, to enable stratification of patients into those 
in whom adjuvant therapy will be required to prevent 
recurrence or to prolong survival (5, 27). 
 In the search for novel therapeutic approaches, 
members of the EGFR/erbB family have emerged as 
attractive objects for targeted therapy. Thus adjuvant 
chemotherapy with the monoclonal antibody 
Trastuzumab to Her-2 (of the EGFR family) has 
become a standard regimen in the treatment of Her-
2-over-expressing breast carcinomas (27). The small 
molecule EGFR-inhibitor gefitinib (ZD 1839, Iressa) 
was approved for the treatment of non-small cell 
lung cancer by the FDA in 2003 (28) and is currently 
being tested in clinical trials of patients suffering from 
colorectal cancer and various other malignancies (27). 
EGFR overexpression has been widely reported in 
urothelial carcinomas of the bladder. However, the 
presence of EGFR has shown significant variation 
between 23% and 95% among different tumours, 
and statistical analyses have also resulted in varying 
conclusions regarding its prognostic significance (27, 
29, 30). The frequent expression on EGFR in urothelial 
carcinomas with squamous and/or glandular 
differentiation is of particular interest, because 
metaplastic features have been shown to; correlate 
with both high tumour stage and grade (31), and also 
correlate with a decreased response to conventional 
radiotherapy (32) and chemotherapy (33). The fact that 
both EGFR expression and metaplastic differentiation 
correlate with high tumour stage and grade suggests 
that EGFR expression may be involved in the 
progression of this particular histological subtype 
(27).
 In this study, we also found that tissue 
overexpression of EGFR in particular correlates well 
with tumour grade with the expression being positive 
in 47.8% of grade 1 tumours compared to 100% in 
grade 3 tumours. However, EGFR expression was 
also found to be positive in the urothelium of  46.4% 
of patients with no tumour recurrence on bladder 
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biopsy. This indicates that, EGFR tissue expression 
will be of prognostic significance only when tissue 
histology is positive for tumour. For the purpose of 
diagnosis, the sensitivity of tissue EGFR positivity is 
higher than urine cytology indicating that in equivocal 
or tiny tissue biopsies, the expression of EGFR may 
assist in clarifying potential neoplasm from benign 
tissue. Leibl et al 2008 (27)showed that TCC with 
metaplastic and glandular  differentiation showed 
strong EGFR expression indicating that strong EGFR 
expression of TCC tumours should be considered in 
patient selection for neoadjuvant therapy as well as 
interpretation of clinical trial targeting EGFR. This 
is because, TCC with metaplastic and glandular 
differentiation have been shown to be more resistant 
to chemotherapy and radiotherapy (27).
 In this study, unlike EGFR expression in tissue 
and urine cytology smears which showed a consistent 
pattern with tumour grade and stage, survivin 
expression did not correlate well with stage or grade. 
This may be because of the type of survivin antibody 
used by us. This is because several different survivin 
antibodies have been used in previous studies and 
nuclear as well as cytoplasmic staining have been 
reported (21, 22). Survivin is known to be associated 
with mitotic apparatus, centromere of chromosomes, 
and mitocondria, and different splice variants were 
also reported to have unique nuclear or mitochondrial 
localisations (34). As polyclonal antibodies tend to 
generate non specific background staining, in this 
study we used a monoclonal antibody raised against 
the full-length human survivin protein to avoid 
this potential pitfall. The survivin IHC pattern we 
observed was predominantly nuclear, with focal 
weak cytoplasmic staining in some cases that we did 
not find to correlate with tumour grade as shown in 
Table 4. A similar observation was made by Chen et 
al 2008 (19). This clean staining pattern suggests that 
some of the previously reported cytoplasmic staining 
with polyclonal anti-survivin antibodies might have 
been background staining, and data correlating 
such cytoplasmic staining to prognosis should be 
interpreted with caution (19). In this study, we failed 
to confirm previous findings by Chen et al (19) who 
showed that survivin scores correlated better and 
had higher predictive value than histology for high 
grade recurrent tumours as only 33.3% of our high 
grade tumours stained positively with survivin.
 The role of EGFR inhibitors in the adjuvant setting 
following cystectomy for muscle invasive urothelial 
cancer has started to receive attention in recent times 
(35). This is because survival remains poor for this 
category of patients. Pruthi et al (35) showed that 
the EGFR inhibitor erlotinib when administered in 
the neoadjuvant setting can have beneficial effects in 
terms of surgical pathology and short-term clinical 
outcomes in patients undergoing radical cystectomy 
for invasive bladder cancer. Thus, the search must 
continue for a better understanding of the molecular 
biology and genetics of cancer which will hopefully 
lead to the identification of a host of candidate targets 
for more specific anticancer treatment (36). Against 
this background, the advent of novel therapeutic 
agents that specifically target these genetic alterations 
may help to revolutionise the treatment of cancers 
and result in improvement of survival with minimal 
toxicity (35, 36). Patients with urothelial tumours with 
positive EGFR expression will be expected to have 
better response to EGFR inhibitors like erlotinib than 
patients with negative or low expression (35).
 A potential limitation of our study is the 
reliability of IHC techniques. IHC is semiquantitative 
and dependent on a range of variables such as the 
choice of antibody used, antibody concentration, 
fixation techniques, variability in the interpretation 
and stratification criteria, inconsistency in specimen 
handling and other technical procedures (5). These 
problems with ‘visual’ IHC can be minimized by the 
use of tissue microarrays using an automated scoring 
system based on brightfield microscopy imaging 
coupled with advanced color detection software (5). 
The adoption of these modern techniques has been 
shown to result in better standardization and greater 
reproducibility of IHC (34, 37, 38).
In conclusion, the present study suggests that 
EGFR immunostaining in tissue and urine cytology 
specimen, but not survivin possibly has prognostic 
and predictive value in the management of patients 
with TCC of the bladder. Visual IHC results are 
difficult to compare and the evaluation of the results 
of immunostaining differ greatly between centers. 
Standardisation of these procedures using microarray 
techniques may improve the results and possibly 
aid in the incorporation of IHC into the overall 
management of patients with urothelial cancer.
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